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Objectives: The Heart Protection Study (HPS) provides an opportunity to assess directly the effects of cholesterol-lowering
therapy on major vascular events (defined as myocardial infarction, coronary death, stroke, or revascularization) in patients
with peripheral arterial disease (PAD). In addition, the effects on peripheral vascular events (ie, non-coronary revasculariza-
tion, aneurysm repairs, major amputations or PAD deaths) can be assessed.
Methods: 6748 UK adults with PAD and 13,788 other high-risk participants were randomly allocated to receive 40 mg
simvastatin daily or matching placebo, yielding an average LDL cholesterol difference of 1.0 mmol/L (39 mg/dL) during a
mean of 5 years.
Results: For participants with PAD, allocation to simvastatin was associated with a highly significant 22% (95% CI 15-29)
relative reduction in the rate of firstmajor vascular event following randomisation (895 [26.4%] simvastatin-allocated vs 1101
[32.7%] placebo-allocated; P < .0001), which was similar to that seen among the other high-risk participants. The absolute
reduction in first major vascular event was 63 (SE 11) per 1000 patients with PAD and 50 (SE 7) per 1000 without
pre-existing PAD. Overall, among all participants, there was a 16% (5-25) relative reduction in the rate of first peripheral
vascular event following randomisation (479 [4.7%] simvastatin vs 561 [5.5%] placebo), largely irrespective of baseline LDL
cholesterol and other factors. This effect chiefly reflects a 20% (8-31) relative reduction in non-coronary revascularization
procedures (334 [3.3%] vs 415 [4.0%]; P  .002).
Conclusion: HPS demonstrates the benefits of cholesterol-lowering statin therapy in patients with PAD, regardless of their
presenting cholesterol levels and other presenting features. Allocation to 40mg simvastatin daily reduces the rate of firstmajor
vascular events by about one-quarter, and that of peripheral vascular events by about one-sixth, with large absolute benefits
seen in participants with PAD because of their high vascular risk. Consequently, statin therapy should be considered routinely
for all patients with PAD. (J Vasc Surg 2007;45:645-54.)1Writing and other Committees are listed in the Appendix, and collaborators
and participating hospitals are listed in reference 17.
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doi:10.1016/j.jvs.2006.12.054Peripheral arterial disease (PAD) is a common condition,
with a prevalence of up to 20% in populations aged over 65
years.1-3 It is associated with a marked increase in cardio-
vascular risk in patients both with and without co-existing
coronary artery disease.4 Observational studies in different
populations indicate a continuous, positive and log-linear
relationship between coronary disease risk and blood cho-
lesterol concentration that extends well below the range
commonly seen in Western populations, without any defi-
nite threshold below which a lower concentration is not
associated with lower risk.5-8 The risk factors for coronary
and peripheral arterial disease are similar, and higher cho-
lesterol concentrations are associated with higher rates of
peripheral arterial disease.9
Despite the high incidence of cardiovascular morbidity
and mortality in patients with PAD, relatively few such
patients had been included in previous randomized con-
trolled trials of cholesterol-lowering statin therapy.10-15 By
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has demonstrated that lowering LDL cholesterol concen-
trations with 40 mg simvastatin daily produces substantial
reductions in the rates of heart attacks, strokes, and revas-
cularization procedures among a wide range of high-risk
individuals, including the large numbers with PAD.16-19
Despite this clear evidence of benefit, almost two-thirds of
patients with PAD are still not receiving statin therapy.20
The aim of the present report is to provide more details
from HPS about the benefits of cholesterol-lowering with
statin therapy in patients with PAD.
PATIENTS AND METHODS
Details of the study have been reported previously16-19
(see also www.hpsinfo.org). In brief, men and women aged
about 40-80 years with non-fasting blood total cholesterol
concentrations of at least 3.5 mmol/L (135 mg/dL) were
eligible provided they had a medical history of coronary
disease, PAD, cerebrovascular disease, diabetes, or treated
hypertension (if also male and aged at least 65 years). PAD
was defined as a history of intermittent claudication (with
or without supporting vascular investigations) or previous
peripheral arterial revascularization procedure, amputa-
tion, or aneurysm repair. People were ineligible if their own
doctor considered statin therapy to be clearly indicated or
contraindicated, or if they hadmyocardial infarction, stroke
or hospital admission for angina within the previous 6
months; chronic liver disease or evidence of abnormal liver
function; severe renal disease or evidence of substantially
impaired renal function; inflammatory muscle disease or
evidence of muscle problems; concurrent treatment with
ciclosporin, fibrates, or high-dose niacin; child-bearing po-
tential; severe heart failure; or other conditions that might
limit long-term compliance.
Statistical analysis. The main comparisons involved
logrank analyses of the first occurrence of particular events
during the scheduled treatment period after randomisation
among all those allocated 40 mg simvastatin daily versus all
those allocated matching placebo tablets (ie, intention-to-
treat).21 These logrank analyses yielded both the event rate
ratio and the test of statistical significance (two-sided prob-
ability value). Assessments of the effects of treatment in
different prespecified subcategories of prior disease (includ-
ing PAD) and of other presenting features were to be based
on first major coronary events (defined as non-fatal myo-
cardial infarction or death from coronary disease), and,
particularly, on the even larger number of first major vas-
cular events (defined as major coronary events, strokes of
any type, and coronary or non-coronary revasculariza-
tions). Tests for heterogeneity or, if more appropriate,
trend were to be used to determine whether the propor-
tional effects observed in specific subcategories differed
clearly from the overall effects (after due allowance for
multiple comparisons and the exploratory nature of some
analyses). Subsidiary comparisons included assessment of
the effects of allocation to simvastatin not just on the rate of
first major vascular events following randomisation, but
also on the numbers of first and subsequent events duringthe scheduled treatment period, and of the effects on
non-coronary vascular procedures (ie, carotid endarterec-
tomy or angioplasty, other arterial grafts or angioplasty,
and amputation). For the purposes of the present report,
exploratory analyses were performed assessing the effects of
statin allocation on peripheral vascular events (defined ret-
rospectively as the first occurrence of a non-coronary revas-
cularization, aneurysm repair, major amputation, or death
from PAD).
Role of the funding sources. The investigators were
responsible for the study design, data collection, data anal-
ysis, data interpretation, and writing of the report, indepen-
dently of all funding sources.
RESULTS
Between July 1994 and May 1997, 6748 people aged
40-80 years with PAD and a further 13,788 high-risk
patients without diagnosed PAD were randomly allocated
to receive 40 mg simvastatin daily or matching placebo
tablets in a double-blind manner (and, separately, using a
two-by-two factorial design, antioxidant vitamins or
matching placebo capsules22). Among participants present-
ing with a history of PAD, 33% had undergone peripheral
arterial surgery or angioplasty and 2% had had an amputa-
tion, while the remainder had symptomatic PAD. Of the
trial participants with PAD, 60% had coronary heart disease
Table I. Baseline characteristics of participants
presenting with or without peripheral artery disease
(PAD)
Baseline Feature
Peripheral
artery disease
(n  6748)
No
peripheral
artery disease
(n  13788)
Age (years) 64.5 (8.1) 63.7 (8.5)
Men 5014 (74%) 10440 (76%)
Smoking
Never regular 1093 (16%) 4081 (30%)
Ex-cigarette 4258 (63%) 8191 (59%)
Current 1397 (21%) 1516 (11%)
Vascular disease
Prior MI 2372 (35%) 6138 (45%)
Other CHD 1675 (25%) 3201 (23%)
Cerebrovascular 521 (8%) 1299 (9%)
Diabetes 1579 (23%) 4384 (32%)
Treated hypertension 2898 (43%) 5559 (40%)
Systolic BP (mmHg) 146 (24) 143 (23)
Diastolic BP (mmHg) 81 (13) 82 (12)
Body mass index (kg/m2) 27.6 (4.4) 27.6 (4.4)
Total cholesterol (mmol/L) 6.0 (1.05) 5.8 (0.99)
LDL cholesterol (mmol/L) 3.5 (0.86) 3.3 (0.80)
HDL cholesterol (mmol/L) 1.04 (0.32) 1.07 (0.33)
Triglycerides (mmol/L) 2.2 (1.42) 2.0 (1.34)
Apolipoprotein A1 (mg/dL) 1.19 (0.22) 1.20 (0.22)
Apolipoprotein B (mg/dL) 1.17 (0.24) 1.13 (0.23)
MI, Myocardial infarction; CHD, coronary heart disease; BP, blood pres-
sure; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Values are mean (and standard deviation) or number of participants (and
percentage).(CHD), 8% had cerebrovascular disease, and 23% had
itivity
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PAD, those who had PADwere more likely to be current or
ex cigarette smokers (84% vs 70%) and had slightly higher
mean total and LDL cholesterol and triglycerides. Diabetes
was less common in the PAD subgroup, largely due to the
selective enrolment of almost 3000 diabetic patients who
did not have overt occlusive arterial disease. The large size
of the study (and the use of minimized randomisation23)
produced good balance between the treatment groups
among participants within both the PAD and non-PAD
groups for themain prognostic features that were measured
(and should have done likewise for those that were not).
Compliance and effect on blood lipids. The mean
duration of follow-up was 5.0 years for all randomized
participants: 5.3 years for those who survived to the sched-
uled end of the study treatment and about half that for
those who did not. Compliance at each follow-up was
defined as at least 80% of the scheduled simvastatin or
Major vascular event Simvastatin Placebo
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(10,269) (10,267)
Major coronary events
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Strokes
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Fig 1. Effects of simvastatin allocation on first majo
pants presenting with or without peripheral artery d
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of each type during follow-up, so there is some non-addplacebo tablets having been taken since the previousfollow-up (based on questioning the participant and review
of remaining calendar-packed tablets). Among all partici-
pants allocated 40 mg simvastatin daily, average statin use
during the scheduled treatment period was 85% (with 82%
compliant with their allocated simvastatin, 3% on non-
study statin alone and 2% on both: Table II, online only).
By contrast, amongst those allocated placebo, an average of
17% were taking non-study statin therapy during the study.
This average absolute difference in statin use of 67% (85%
minus 17%) between all participants allocated simvastatin
and all those allocated placebo yielded an average difference
in LDL cholesterol of 1.0 mmol/L (suggesting that actual
use of 40 mg simvastatin would reduce LDL cholesterol by
an average of about 1.5 mmol/L in this population).
Non-study statin use in the placebo group was more com-
mon among those who already had diagnosed coronary
disease at entry, were younger or had higher pre-treatment
LDL cholesterol concentrations, but it was not influenced
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follow-up were similar in those with and without PAD at
baseline.
Effects on major vascular events in the presence and
absence of PAD. Overall, allocation to simvastatin pro-
duced a very highly significant 24% (95% CI 19-28; P 
.0001) proportional reduction in the first occurrence of a
major vascular event following randomisation (Fig 1).
Among the participants with diagnosed PAD at study entry
there was a highly significant 22% (15-29; P  .0001)
proportional reduction in major vascular events, which was
similar to the 25% (20-31; P .0001) reduction among the
other high-risk participants studied (heterogeneity P  .5)
Similar proportional reductions were also observed among
patients with or without PAD in the rates of first major
coronary event, stroke, and revascularizations considered
separately (Fig 1). The 24% (17-30; P  .0001) reduction
in the rate of any revascularization procedure observed
among all participants reflected a 30% (22-38; P  .0001)
reduction in coronary revascularizations and a 16% (5-26; P
 .006) reduction in non-coronary revascularizations (in-
Fig 2. Absolute effects of simvastatin allocation
participants subdivided by prior PAD. S, Simvastatin
represents percentage having a revascularization duringcluding amputations), with similar proportional reductionsobserved in those with and without PAD. The absolute
reduction in major vascular events was somewhat greater in
participants with PAD at baseline (63 [SE 11] per 1000)
than in those without PAD (50 [SE 7] per 1000: Fig 2).
This reflected a greater absolute reduction in revasculariza-
tions among participants with PAD (42 [SE 9] per 1000)
than among those without PAD (19 [SE 5] per 1000).
Effects on major vascular events in different cir-
cumstances among participants with PAD and other
participants. The extreme statistical significance of the
overall reduction in the rate of first major vascular events
(z-score 9.3), and the large number of events on which it
is based, allows reliable assessment of the effects of treat-
ment in various different categories of patient. The relative
risk reduction among participants with or without diag-
nosed PAD at study entry was about a quarter in each of the
subcategories studied (Fig 3 and Fig 4). In particular,
among the 2701 patients with PAD but no pre-existing
coronary disease, there was a significant 22% reduction in
first major vascular events (327 [24.7%] simvastatin vs 420
[30.5%] placebo), which was similar to the effect in the
-year rates of first major vascular events among
ated; P, placebo-allocated. Shaded portion of each bar
-up.on 5
allocother patients (heterogeneity P  .9: Fig 4). The propor-
me o
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PAD also appeared to be about a quarter, irrespective of
their history of other vascular disease, diabetes, sex, or age
(Fig 3 and Fig 4). Most notably, the proportional reduction
in risk did not appear to be materially influenced by the
pre-treatment lipid concentrations. So, for example, there
was a highly significant 20% (6-32; P  .006) reduction
amongst the 2034 PAD participants whose pre-treatment
measurements of LDL cholesterol were below 3.0mmol/L
(116 mg/dL), which was similar to the highly significant
25% (13-34; P  .0001) reduction seen among other
high-risk individuals recruited with LDL cholesterol below
3.0 mmol/L (Fig 4). Furthermore, this proportional re-
duction in risk was independent of the nature of partici-
pants’ pre-existing peripheral arterial disease, with a highly
significant 24% reduction (13-33; P  .0002) among the
2339 patients with prior peripheral arterial revasculariza-
tions/amputations and a similar, highly significant, 21%
reduction (11-29; P  .0001) seen among the remaining
4409 patients with PAD.
Prevention of first and subsequent major vascular
events among participants with PAD. Overall in this
high-risk population of patients with and without PAD,
2585 (25.2%) placebo-allocated participants had a first
major vascular event following randomisation during mean
follow-up of 5 years, and allocation to simvastatin reduced
this rate by about a quarter (Fig 1). But, these 2585
patients had 3697 first or subsequent major vascular events
during this follow-up period, and the rate of these subse-
Prior disease Vascular events/people (&
categories Simvastatin Plac
PAD
+ CHD   568/  2059 (27.6%)   681/  1988
+ Cerebrovascular   182/   554 (32.9%)   227/   584
+ Diabetes mellitus   256/   787 (32.5%)   309/   792
+ None of above   163/   699 (23.3%)   208/   766
Any PAD                  895/  3384 (26.4%)  1101/  3364
No PAD
+ CHD   891/  4635 (19.2%)  1160/  4704
+ Cerebrovascular   224/  1091 (20.5%)   261/  1051
+ Diabetes mellitus   345/  2191 (15.7%)   439/  2193
No PAD                  1138/  6885 (16.5%)  1484/  6903
ALL PATIENTS  2033/10269 (19.8%)  2585/10267
Fig 3. Effects of simvastatin allocation on major v
conventions as in figure 1. There is no overlap betwe
categories, but within each of these categories there is soquent events was also reduced (Table III). Hence, whereasthe 1.0 mmol/L reduction in LDL cholesterol observed on
average during the study typically prevented 54 (SE 6)
participants per 1000 from having at least one major vas-
cular event, it prevented 91 (10) first or subsequent major
vascular events per 1000 patients during this 5-year period
of follow-up. These absolute benefits are evenmoremarked
in participants with PAD, in whom allocation to simvastatin
prevented 63 (11) per 1000 from having at least one major
vascular event, and prevented 116 (21) first or subsequent
major vascular events.
Effects on peripheral vascular events subdivided by
prior PAD and other characteristics. Overall, allocation
to simvastatin was associated with a significant 16% (5-25; P
 .006) proportional reduction in the rate of first periph-
eral vascular event following randomisation (479 [4.7%]
simvastatin-allocated vs 561 [5.5%] placebo-allocated),
which was not significantly influenced by baseline charac-
teristics, including prior PAD, coronary disease, diabetes,
age, or pre-treatment lipid levels (Fig 5). But, since the
patients with PAD were at particularly high risk of periph-
eral vascular events, this relative risk reduction translated
into much larger absolute reductions in participants with
pre-existing PAD (20 [SE 8] per 1000) than in those
without PAD (3 [SE 2] per 1000: Fig 5). The overall
reduction in peripheral vascular events was due chiefly to a
20% relative reduction in non-coronary revascularizations
(334 [3.3%] simvastatin vs 415 [4.0%] placebo; P .002),
reflecting significant reductions in both carotid endarterec-
tomy or angioplasty (42 [0.4%] vs 82 [0.8%]; P  .0003)
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apparent effect on the incidence of aneurysms repairs or
deaths (120 [1.2%] vs 113 [1.1%]; P  .7) or of amputa-
tions (95 [0.9%] vs 103 [1.0%]; P  .5).
Safety. Simvastatin 40 mg daily was well tolerated
during the trial, with no significant effect on liver enzymes
or other adverse effects. Myopathy (muscle pain and/or
weakness associated with an elevation in creatine kinase
10 ULN) is a recognized rare side-effect of all statins,
but the estimated excess risk with this dose of simvastatin
was only about 1 per 10,000 patients per year.17
DISCUSSION
HPSprovides the first reliable evidence that cholesterol-
lowering statin therapy can produce substantial reductions
of around one-quarter in the risk of major vascular events
(heart attacks, strokes and revascularizations) among peo-
ple with PAD, even if they do not already have manifest
coronary disease. These beneficial effects are largely irre-
alPnitatsavmiSDAP enilesaB
olla-detacolla-serutaef rehto &
Prior disease
CHD: PAD   568/  2059 (27.6%)   681/  19
          no PAD   891/  4635 (19.2%)  1160/  47
No CHD: PAD   327/  1325 (24.7%)   420/  13
               no PAD   247/  2250 (11.0%)   324/  21
Prior diabetes
Diabetes: PAD   256/   787 (32.5%)   309/   7
                no PAD   345/  2191 (15.7%)   439/  21
No diabetes: PAD   639/  2597 (24.6%)   792/  25
                     no PAD   793/  4694 (16.9%)  1045/  47
Gender
Male: PAD   724/  2521 (28.7%)   887/  24
          no PAD   942/  5206 (18.1%)  1248/  52
Female: PAD   171/   863 (19.8%)   214/   8
              no PAD   196/  1679 (11.7%)   236/  16
Age (years)
<65: PAD   376/  1553 (24.2%)   457/  15
        no PAD   455/  3350 (13.6%)   634/  33
>_65: PAD   519/  1831 (28.3%)   644/  18
        no PAD   683/  3535 (19.3%)   850/  35
Total cholesterol (mmol/L)
<5.0: PAD   140/   583 (24.0%)   191/   6
         no PAD   220/  1447 (15.2%)   281/  14
>_5.0: PAD   755/  2801 (27.0%)   910/  27
         no PAD   918/  5438 (16.9%)  1203/  54
LDL cholesterol (mmol/L)
<3.0: PAD   260/  1024 (25.4%)   314/  10
         no PAD   338/  2365 (14.3%)   442/  23
>_3.0: PAD   635/  2360 (26.9%)   787/  23
         no PAD   800/  4520 (17.7%)  1042/  45
HDL cholesterol (mmol/L)
<0.9: PAD   372/  1276 (29.2%)   468/  12
         no PAD   446/  2341 (19.1%)   596/  23
>_0.9: PAD   523/  2108 (24.8%)   633/  21
         no PAD   692/  4544 (15.2%)   888/  45
ALL PATIENTS  2033/10269 (19.8%)  2585/102
Fig 4. Effects of simvastatin allocation on first ma
subdivided by other presenting features. Symbols and
values at the initial screening visit prior to starting any stytienegoreteHoitar etar tnevEobec
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76 (30.5%)
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10 (22.2%)
93 (35.6%) p=0.7
34 (23.8%)
71 (24.6%)
69 (14.1%)
51 (29.5%) p=0.5
85 (18.7%)
13 (35.5%)
18 (24.2%)
02 (31.7%) p=0.8
40 (19.5%)
62 (32.9%)
63 (22.0%)
10 (31.1%) p=0.9
94 (18.5%)
54 (33.4%)
09 (23.1%)
52 (37.4%) p=0.4
07 (25.8%)
12 (30.0%)
96 (19.3%)
67 (25.2%) 0.76 (0.72 - 0.81)
p<0.0001
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jor vascular event in participants with or without PAD
 conventions as in Fig 1. Lipid categories relate to measuredspective of baseline cholesterol and independent of, andTable III. Effects of simvastatin allocation on first and all
major vascular events in participants with or without PAD
Event
Number of events
Events (SE) avoided
per 1000 patients
allocated simvastatin
Simvastatin-
allocated
Placebo-
allocated
PAD
First events 895 1101 63 (11)
All events 1327 1709 116 (21)
No PAD
First events 1138 1484 50 (7)
All events 1436 1988 79 (10)
All patients
First events 2033 2585 54 (6)
All events 2763 3697 91 (10)
r amp
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patients (including anti-hypertensive therapy and various
other types of cardio-protective drugs). The absolute ben-
efits in participants with PAD were at least as great as
among the other high-risk groups studied, and involved a
greater absolute reduction in non-coronary revasculariza-
tion procedures.
Observational studies suggest that patients with overt
PAD tend to be less well managed in terms of risk factor
modification than patients with manifest coronary disease,
despite their similar (or even higher) vascular risk, with as
few as one-third of patients with PAD receiving statin
therapy.20 Prior to HPS, the role of lipid lowering therapy
in the PAD population was unclear. A meta-analysis of
“pre-statin” trials of lipid-lowering interventions24 and a
subsequent larger study of bezafibrate in men with PAD25
did not provide clear evidence of benefit, and few patients
with PAD were included in other randomized statin trials.
By contrast, the present analyses of HPS show that contin-
ued statin treatment prevents not just the first occurrence of
major vascular events in patients with PAD but also pre-
vents subsequent events. Hence, among the 63 PAD par-
ticipants per 1000 in HPS who avoided at least one major
vascular event during 5 years of allocated simvastatin treat-
ment, 116 first or subsequent major vascular events were
avoided. Due in part to this effect on both first and subse-
quent events, an economic analysis of HPS has shown that
40 mg daily simvastatin should generally be cost-saving for
patients with PAD.26
Because of its large size and the inclusion of almost
7000 individuals with pre-existing PAD, many more par-
ticipants in HPS suffered peripheral vascular events than in
any other randomized trial of cholesterol-lowering therapy
calPnitatsavmiSgnitneserP
olla-detacolla-erutaef
Prior disease
33 /504  )%1.01(4833 /143  DAP
No PAD   138/  6885 (2.0%)   156/  69
Coronary disease
66 /203  )%7.3(4966 /052  seY
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Fig 5. Effects of simvastatin allocation on first peri
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a non-coronary revascularization, aneurysm repair, majo(in which such events were either not recorded or occurredtoo infrequently to allow a reliable estimation of the effect
of allocated therapy). Consequently, HPS is able to dem-
onstrate reliably that statin therapy produces a definite
reduction of around one-sixth in the risk of peripheral
vascular events, both among patients with pre-existing
PAD and among the other high-risk individuals studied
who did not have diagnosed PAD. The magnitude of the
relative reduction observed in peripheral vascular events is
somewhat smaller than that observed in major coronary
events, strokes or all revascularizations. This smaller effect
on peripheral events may be due to the play of chance, or
the more insidious nature of peripheral arterial disease (in
which progression from intermittent claudication to critical
limb ischemia and amputation is uncommon27), or the
inclusion of outcomes that are not influenced by treatment.
In particular, whereas allocation to simvastatin produced a
20% reduction in the rate of non-coronary revascularization
procedures, there was no apparent effect on the incidence
of amputations or fatal or repaired aneurysms (although,
there were too few such events to rule out favorable ef-
fects). Long-term follow-up of HPS participants is ongo-
ing, and it remains possible that evidence of benefit on
these outcomes may still emerge.
Previous placebo-controlled trials and observational
studies have suggested a beneficial effect of statin therapy
on intermittent claudication by retarding symptom pro-
gression,28-32 but the development or worsening of inter-
mittent claudication was not systematically recorded in
HPS. Despite this, the results of HPS clearly demonstrate
that statin therapy should be considered for all patients with
intermittent claudication to reduce their very significant
risk of cardiovascular mortality and major morbidity. Fur-
thermore, these intention-to-treat results probably under-
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r eveestimate the benefits of taking 40 mg simvastatin daily.
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about 1.0 mmol/L (39 mg/dL) that was observed be-
tween all those allocated simvastatin and all those allocated
placebo represents only about two-thirds of the LDL cho-
lesterol difference produced by the actual use of 40 mg
simvastatin daily (due to the “drop-out” and “drop-in” rate
of around one-sixth in those allocated simvastatin and
placebo respectively). Similarly, the reduction of about a
quarter in major vascular events in these intention-to-treat
comparisons is likely to represent only about two-thirds of
the risk reduction produced by actual compliance with this
statin regimen.Hence, actual use of 40mg simvastatin daily
would lower LDL cholesterol by about 1.5 mmol/L (58
mg/dL) in this population and would probably reduce the
rates of heart attacks, strokes, and revascularisations by
about one-third and the rates of peripheral vascular events
by about one-quarter.
HPS clearly demonstrates the benefits of cholesterol-
lowering statin therapy in patients with PAD, safely pro-
ducing highly significant reductions in cardiovascular mor-
bidity and mortality in this high-risk group. In addition,
statin use reduced the incidence of peripheral vascular
events in all of the high-risk groups studied. These benefi-
cial effects are largely irrespective of baseline cholesterol
levels or other features. Consequently, statin therapy
should be considered routinely for all people with, or at risk
of, peripheral arterial disease.
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Dr Matthew Dougherty (Philadelphia, Pa). There is no
question, the statistics don’t lie, that there is a benefit, but I’m
impressed with your data offered per thousand patients. If I read it
correctly, there is about a 2% absolute reduction in peripheral
vascular events over a 5-year period, even in the PAD group, which
seems like a pretty small number. And I wonder whether you have
done any cost–benefit analysis to achieve that 0.4% per year reduc-
tion?
Dr Richard Bulbulia. Considering major vascular events, an
economic analysis of HPS has shown that, at 2001 prices, 40 mg
simvastatin is cost effective for all study participants. And, with
patent expiry, the price of simvastatin is falling and it should be
cost-saving for all HPS participants, particularly for those with
PAD who actually derived the largest absolute benefits from statin
therapy, with an absolute reduction in MVE of around 6%.
Dr Michael Conte (Boston, Mass). Congratulations to you
and your coauthors for another outstanding contribution. For
those who are not familiar with it, the original report from the
Heart Protection Study was published a couple of years ago in The
Lancet. This is an important follow-up to that study focused on our
peripheral vascular patients, and I have a couple of questions. First,
can you tell us if the presence or absence of diabetes affected the
outcome in relation to statins? Was the apparent benefit of statins
more or less enriched in the diabetic population?
Second, can you tell us a little bit more about the timing of the
events in the PADpatients? Did you observe a uniform distribution
of risk reduction over time, or was the effect seen mostly within the
first year or two after randomization?
Finally, what can you tell us about antiplatelet therapy in the
trial?
Dr Bulbulia. The beneficial effect of simvastatin was not
influenced by the presence or absence of diabetes at baseline. A
reduction in major vascular events was seen after around 1 year of
treatment; however, in the recent Cholesterol Treatment Trialists
Meta-analysis of over 91,000 participants, benefits emerge within
the first year. Finally, the benefits seen with statin therapy were
additional to, and therefore independent of, any other treatments,Dr Eric Wahlberg (Stockholm, Sweden). Did you have a
chance to look at the patients with PAD without cardiac disease at
all? Could you also enlighten me if this paper differs anything from
your previous publication from the HPS study, besides the analysis
of the peripheral vascular events?
Dr Bulbulia. Around 2700 patients with PAD had no pre-
existing coronary artery disease at baseline, and they achieved
similar proportional benefits as those with CAD and PAD. This
presentation provides more detailed analyses of the PAD subgroup
in HPS and emphasizes that all such patients should be on a statin.
Observational studies suggest that less than one third of our
patients are currently receiving appropriate lipid-lowering therapy.
In addition, we have shown a reduction in peripheral vascular
events with statin allocation, which has not been reported in any
previous study.
Dr Thomas Lindsay (Toronto, Ontario, Canada). I would
applaud this as probably the first study that demonstrates the
benefit of statin therapy in a predominantly PAD group, so I think
it’s very important data. I have a couple of questions. First, what
was the number needed to treat in order to prevent an event in the
PAD subgroup vs the non-PAD subgroup?
Secondly, you said that the overall reduction in cholesterol was
1 mmol/L. Is there a better benefit with greater reductions in
cholesterol level? Was there a dose-response in terms of the pa-
tients’ benefit?
Third, many of these patients also have elevated triglycerides,
which are in fact, much more difficult to treat. Was the effect of
statin therapy dependent or independent of elevated triglyceride
levels?
Dr Bulbulia. The number needed to treat to prevent a first
major vascular event was 16 in the PAD subgroup and 20 in those
without PAD. The effects of statin therapy were independent of
baseline lipid profiles, including triglycerides. Finally, there is a
trend towards using higher doses of statins in high-risk patients.
Indeed the recent CTT meta-analysis suggests that an increased
reduction in LDL cholesterol may result in increased benefits.
DrLindsay.What would you say is an appropriate LDL target
level? As vascular surgeons take hold of risk reduction in our
patient population, we really need to have some target to treat to.
JOURNAL OF VASCULAR SURGERY
April 2007654 Heart Protection Study Collaborative GroupYour first slide implied the lower the better. We see the cardiolo-
gists going from what used to be levels of 3 mmol/L down to 2 for
LDL to now less than 2. Based on this data, what threshold would
you recommend for trying to get a patient’s LDL cholesterol to?
Dr Bulbulia. There should be no threshold for initiation of
statin therapy. HPS was not a target-finding study, but results from
some “more vs less” statin trials suggest that higher doses of statin
therapy will reduce cardiac and noncardiac vascular events further.
However, the question is whether the risks of side effects associated
with statins, which are dose-dependent, justify this approach.
Dr Jacob Lustgarten (Chevy Chase,Md). Did you notice any
morbidity and mortality benefits in patients who underwent sur-
statin therapy specifically in the PAD population. The major newgery? Statins are increasingly associated with a plaque stabilization
effect and a lower perioperative rate of adverse cardiac events, and
even a lower stroke risk after carotid surgery. It seems almost like
these patients should be on statins much the way -blockers are
used. You followed a large number of randomized patients. Did
you look for this effect?
Dr Bulbulia. We have not performed such an analysis, but I
am aware of the results of observational and smaller interventional
studies suggesting improved outcomes with statin therapy in the
perioperative period. However, our results clearly demonstrate
that all these patients should be on a statin before, during, and after
their operation.INVITED COMMENTARYWilliam R. Hiatt, MD, Denver, Colo
Current guidelines give a class I recommendation to lower
low-density lipoprotein (LDL) cholesterol levels below 100
mg/dL in all patients with peripheral artery disease (PAD) and a
class IIa recommendation to lower the LDL cholesterol level
below 70 mg/dL in patients who are at “very high risk of ischemic
events.”1 High-risk PAD would be defined as more than one
vascular bed involved—eg, a clinical history of concomitant coro-
nary or cerebral vascular disease. The primary evidence for these
recommendations comes from the original publication of the
Heart Protection Study that evaluated the benefits of simvastatin in
over 20,000 high-risk patients.2 There were 6748 patients with
PAD reported in the original publication, and these patients had a
reduction in fatal and nonfatal cardiovascular events with simvasta-
tin similar to that in patients with other forms of atherosclerosis. A
recent meta-analysis of statin therapy in a broad population of
high-risk patients demonstrated that there was a consistent benefit
in reduction of risk of cardiovascular events across a wide popula-
tion of patients and a wide range of baseline LDL cholesterol
levels.3 Thus there is a broad consensus to treat all patients at risk
with statin drugs, regardless of their baseline cholesterol level.
The publication of the Heart Protection Study Collaborative
Group in the Journal of Vascular Surgery focuses on the benefits offinding was a significant reduction in noncoronary revasculariza-
tions. Confirmatory findings were the consistency of the benefit
across all populations studied (including patients with PAD who
had no pre-existing coronary artery disease) and benefit regardless
of baseline LDL cholesterol level. There was no benefit of the statin
in preventing amputations, perhaps reflecting the end-stage patho-
physiology of patients who suffer limb loss.
Themessage is clear. All patients with PAD are at high risk and
meet criteria for statin therapy. The benefit of statin therapy is
primarily systemic (prevention of major cardiovascular events) but
also local (reduction of the need for revascularization).
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during follow-up
Presenting features
Use of study/
non-study statin (%)
Simvastatin-
allocated
Placebo-
allocated
Prior CHD
CHD: PAD 84% 21%
no PAD 87% 20%
No CHD: PAD 82% 12%
no PAD 83% 11%
Age (years)
65: PAD 83% 21%
no PAD 85% 20%
65: PAD 83% 14%
no PAD 86% 15%
Total cholesterol (mmol/L)
5.0: PAD 81% 5%
no PAD 84% 5%
5.0: PAD 84% 20%
no PAD 86% 21%
LDL cholesterol (mmol/L)
3.0: PAD 81% 7%
no PAD 84% 8%
3.0: PAD 84% 22%
no PAD 87% 22%
All patients 85% 17%
CHD, Coronary heart disease.
*The absolute difference in LDL cholesterol that would be produced by full
columns (for example, –1.0/67%  –1.5 mmol/L).-study), and average plasma LDL cholesterol concentrations,
Absolute
difference*
Plasma LDL cholesterol
(mmol/L)
Absolute
difference*
Simvastatin-
allocated
Placebo-
allocated
63% 2.4 3.2 –0.8
67% 2.3 3.2 –1.0
70% 2.4 3.4 –1.0
72% 2.2 3.2 –1.0
62% 2.4 3.3 –0.9
65% 2.3 3.2 –0.9
69% 2.3 3.3 –0.9
71% 2.2 3.3 –1.1
75% 1.8 2.6 –0.8
79% 1.7 2.7 –0.9
64% 2.5 3.4 –0.9
66% 2.4 3.4 –1.0
74% 1.9 2.7 –0.8
76% 1.8 2.8 –0.9
62% 2.6 3.5 –0.9
64% 2.5 3.5 –1.0
67% 2.3 3.3 –1.0
compliance with 40mg simvastatin daily can be estimated as the ratio of these two
